Preliminary Results Demonstrate That the Novel Delivery of Dexamethasone via Mercator`s Platform Micro-Infusion Catheter Inhibits Restenosis for at Least 9 Months in 10 Patients Treated for Peripheral Vascular Disease (PAD)